marketshareAI

Hikma Pharmaceuticals

HIKHealthcare
2,066.00GBX
-0.58%
Market Cap
4.55B
Volume
17.33k
3% of avg
P/E Ratio
11.61
EPS (TTM)
1.78
Beta
0.63
Day Range
2,060.00p - 2,082.00p
52 Week Range
1,751.00p2,066.00p2,360.00p
2,066.00p

Upcoming Events

July 9, 2025
Maturity of $500 million Eurobond
High Impact Event
7 August 2025
Announcement of interim results for the six months ended 30 June 2025
September 8, 2026
Amarin Pharma Inc. v. Hikma Pharmaceuticals PLC trial start date
High Impact Event
January 2030
Group revenue target of $5 billion
High Impact Event
HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director Share Transactions

The pharmaceutical company announces share transactions by its executive chairman, executive vice chairman, and non-executive director.

HIK
NEUTRAL

Hikma Pharmaceuticals Provides Medium-Term Guidance Ahead of US Site Visit

The pharmaceutical company has announced medium-term guidance for revenue and profit growth ahead of a site visit in the US.

HIK
NEUTRAL

Hikma Pharmaceuticals Directors Increase Shareholdings

The pharmaceutical company's directors have increased their shareholdings in the business through a dividend reinvestment plan.

HIK
NEUTRAL

S&P Upgrades Hikma Pharmaceuticals to 'BBB' Rating

The pharmaceutical company receives an upgrade to its credit rating from S&P, strengthening its investment grade status.

HIK
NEUTRAL

Hikma Reaches Settlement Agreement for Xyrem® US Lawsuits

The pharmaceutical company has reached a settlement agreement to resolve the majority of its Xyrem® (sodium oxybate) antitrust class action cases in the US, subject to court approval.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director/PDMR Shareholding

The pharmaceutical company has announced changes to director and PDMR shareholdings.

HIK
NEUTRAL

Hikma Pharmaceuticals Reiterates Full Year Guidance Amid Challenging Conditions

The pharmaceutical company reiterates full year guidance despite facing broader geopolitical challenges and increased competition in some product areas.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director and PDMR Share Awards

The pharmaceutical company has granted share awards to its executive team as part of long-term incentive plans.

HIK
NEUTRAL

Hikma Pharmaceuticals Announces Director/PDMR Shareholding

The pharmaceutical company has announced a change in shareholding by a non-executive director.

HIK
NEUTRAL

Hikma Pharmaceuticals Publishes 2024 Annual Report and AGM Notice

The pharmaceutical company has released its 2024 Annual Report and notice of the upcoming AGM.